Antiphospholipid autoantibodies as blood biomarkers for detection of early stage Alzheimer's disease

Autoimmunity

Volumn 48, Issue 5, 2015, Pages 344-351

  McIntyre, John A ^a,b   Ramsey, Curtis J ^c   Gitter, Bruce D ^d   Saykin, Andrew J ^e   Wagenknecht, Dawn R ^a,b   Hyslop, Paul A ^b  

^a Franciscan St Francis Cancer Center   (United States)

^b Lilly USA   (United States)

^c Curtis Ramsey and Associates   (United States)

^d INDIANA UNIVERSITY SCHOOL OF DENTISTRY   (United States)

^e INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ELISA; Mild cognitive impairment; Neurodegenerative disease; Redox reactive antiphospholipid autoantibodies; Serum biomarkers

Indexed keywords

BIOLOGICAL MARKER; PHOSPHOLIPID ANTIBODY; IMMUNOGLOBULIN G;

AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DEMENTIA; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; MALE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NEUROIMAGING; PILOT STUDY; SENSITIVITY AND SPECIFICITY; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGY; PROGNOSIS; REPRODUCIBILITY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTIBODIES, ANTIPHOSPHOLIPID; BIOMARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; MALE; PILOT PROJECTS; PROGNOSIS; REPRODUCIBILITY OF RESULTS;

EID: 84942509989     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.3109/08916934.2015.1008464     Document Type: Article

References (50)

1. Alzheimer's disease facts and figures. 2014. Alzheimers Dement. 10: 1-76.
2. Alkalay, A., G. D. Rabinovici, G. Zimmerman, et al. 2013. Plasma acetylcholinesterase activity correlates with intracerebral betaamyloid load. Curr. Alzheimer Res. 10: 48-56.
3. Alsadany, M. A., H. H. Shehata, M. I. Mohamad, and R. G. Mahfouz. 2013. Histone deacetylases enzyme, copper, and IL-8 levels in patients with Alzheimer's disease. Am. J. Alzheimers Dis. Other Demen. 28: 54-61.
4. Bai, L., N. Song, J. Yu, et al. 2013. Elevated plasma levels of soluble TNFRs and TACE activity in Alzheimer's disease patients of Northern Han Chinese descent. Curr. Alzheimer Res. 10: 57-62.
5. Honma, T., K. Hatta, Y. Hitomi, et al. 2013. Increased systemic inflammatory interleukin-1ss and interleukin-6 during agitation as predictors of Alzheimer's disease. Int. J. Geriatr. Psychiatry 28: 233-241.
6. Liang, F., J. Jia, S. Wang, et al. 2013. Decreased plasma levels of soluble low density lipoprotein receptor-related protein-1 (sLRP) and the soluble form of the receptor for advanced glycation end products (sRAGE) in the clinical diagnosis of Alzheimer's disease. J. Clin. Neurosci. 20: 357-361.
7. Lopez, N., C. Tormo, I. De Blas, et al. 2013. Oxidative stress in Alzheimer's disease and mild cognitive impairment with high sensitivity and specificity. J. Alzheimers Dis. 33: 823-829.
8. Huang, C. W., S. J. Wang, S. J. Wu, et al. 2013. Potential blood biomarker for disease severity in the taiwanese population with Alzheimer's disease. Am. J. Alzheimers Dis. Other Demen. 28: 75-83.
9. May, J. E., R. M. Pemberton, J. P. Hart, et al. 2013. Use of whole blood for analysis of disease-associated biomarkers. Anal. Biochem. 437: 59-61.
10. Leung, R., P. Proitsi, A. Simmons, et al. 2013. Inflammatory proteins in plasma are associated with severity of Alzheimer's disease. PLoS One 8: e64971.
11. Laske, C., M. Schmohl, T. Leyhe, et al. 2013. Immune profiling in blood identifies sTNF-R1 performing comparably well as biomarker panels for classification of Alzheimer's disease patients. J. Alzheimers Dis. 34: 367-375.
12. Ray, S., M. Britschgi, C. Herbert, et al. 2007. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat. Med. 13: 1359-1362.
13. O'Bryant, S. E., G. Xiao, R. Barber, et al. 2011. A blood-based algorithm for the detection of Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 32: 55-62.
14. Soares, H. D., W. Z. Potter, E. Pickering, et al. for the Biomarkers Consortium Alzheimer's Disease Plasma Proteomics. 2012. Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer Disease. Arch. Neurol. 69:1-8.
15. Doecke, J. D., S. M. Laws, N. G. Faux, et al. 2012. Blood-based protein biomarkers for diagnosis of Alzheimer disease. Arch. Neurol. 69: 1318-1325.
16. Ray, L., V. K. Khemka, P. Behera, et al. 2013. Serum homocysteine, dehydroepiandrosterone sulphate and lipoprotein (a) in Alzheimer's disease and vascular dementia. Aging Dis. 4: 57-64.
17. Hye, A., J. Riddoch-Contreras, A. L. Baird, et al. 2014. Plasma proteins predict conversion to dementia from prodromal disease. Alzheimers Dement. 6: 799-807.
18. Cheng, L., R. A. Sharples, B. J. Scicluna, and A. F. Hill. 2014. Exosomes provide a protective and enriched source of miRNA for biomarker profiling compared to intracellular and cell-free blood. J. Extracell. Vesicles 3. doi: 10.3402/jev.v3.23743.
19. Bekris, L. M., F. Lutz, T. J. Montine, et al. 2013. MicroRNA in Alzheimer's disease: an exploratory study in brain, cerebrospinal fluid and plasma. Biomarkers: Biochem. Indicat. Exposure Response Suscept. Chem. 18: 455-466.
20. Fiandaca, M. S., D. Kapogiannis, M. Mapstone, et al. 2014. Identification of preclinical Alzheimer's disease by a profile of pathogenic proteins in neurally derived blood exosomes: a casecontrol study. Alzheimers Dement. doi:10.1016/j.jalz.2014.06.008.
21. Kapogiannis, D., A. Boxer, J. B. Schwartz, et al. 2014. Dysfunctionally phosphorylated type 1 insulin receptor substrate in neural-derived blood exosomes of preclinical Alzheimer's disease. FASEB J. doi:10.1096/fj.14-262048.
22. Bruce-Keller, A. J., S. Gupta, T. E. Parrino, et al. 2010. NOX activity is increased in mild cognitive impairment. Antioxid. Redox. Signal. 12: 1371-1382.
23. Smith, M. A., X. Zhu, M. Tabaton, et al. 2010. Increased iron and free radical generation in preclinical Alzheimer disease and mild cognitive impairment. J. Alzheimers Dis. 19: 363-372.
24. Padurariu, M., A. Ciobica, L. Hritcu, et al. 2010. Changes of some oxidative stress markers in the serum of patients with mild cognitive impairment and Alzheimer's disease. Neurosci. Lett. 469: 6-10.
25. Lavados, M., M. Guillon, M. C. Mujica, et al. 2008. Mild cognitive impairment and Alzheimer patients display different levels of redox-active CSF iron. J. Alzheimers Dis. 13: 225-232.
26. Levin, E. C., N. K. Acharya, M. Han, et al. 2010. Brain-reactive autoantibodies are nearly ubiquitous in human sera and may be linked to pathology in the context of blood-brain barrier breakdown. Brain Res. 1345: 221-232.
27. Koehler, N. K., E. Stransky, M. Shing, et al. 2013. Altered serum IgG levels to alpha-synuclein in dementia with lewy bodies and Alzheimer's disease. PLoS One 8: e64649.
28. Gnanapavan, S., D. Grant, G. Pryce, et al. 2012. Neurofilament a biomarker of neurodegeneration in autoimmune encephalomyelitis. Autoimmunity 45: 298-303.
29. McIntyre, J. A., D. R. Wagenknecht, and W. P. Faulk. 2006. Redoxreactive autoantibodies: detection and physiological relevance. Autoimmun. Rev. 5: 76-83.
30. McIntyre, J. A., D. R. Wagenknecht, and W. P. Faulk. 2005. Autoantibodies unmasked by redox reactions. J. Autoimmun. 24: 311-317.
31. McIntyre, J. A., D. R. Wagenknecht, and C. J. Ramsey. 2009. Redox-reactive antiphospholipid antibody differences between serum from Alzheimer's patients and age-matched controls. Autoimmunity 42: 646-652.
32. McIntyre, J. A., J. Chapman, E. Shavit, R. L. Hamilton, and S. T. Dekosky. 2007. Redox-reactive autoantibodies in Alzheimer's patients' cerebrospinal fluids: preliminary studies. Autoimmunity 40: 390-396.
33. McIntyre, J. A., R. L. Hamilton, and S. T. DeKosky. 2007. Redoxreactive autoantibodies in cerebrospinal fluids. Ann. N. Y. Acad. Sci. 1109: 296-302.
34. Li, S. D., Y. D. Su, M. Li, and C. G. Zou. 2006. Hemin-mediated hemolysis in erythrocytes: effects of ascorbic acid and glutathione. Acta Biochim. Biophys. Sin. 38: 63-69.
35. McIntyre, J. A., D. R. Wagenknecht, and W. P. Faulk. 2003. Antiphospholipid antibodies: discovery, definitions, detection and disease. Prog. Lipid Res. 42: 176-237.
36. Nishida, T., and F. A. Kummerow. 1962. Interaction of low-density lipoproteins of serum with hemin. J. Lipid Res. 3: 448-455.
37. Agar, C., G. M. van Os, M. Morgelin, et al. 2010. Beta2-glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome. Blood 116: 1336-1343.
38. Sugi, T., and J. A. McIntyre. 1995. Autoantibodies to phosphatidylethanolamine (PE) recognize a kininogen-PE complex. Blood 86: 3083-3089.
39. McIntyre, J. A., D. R. Wagenknecht, and T. Sugi. 1997. Phospholipid binding plasma proteins required for antiphospholipid antibody detection-an overview. Am. J. Reprod. Immunol. 37: 101-110.
40. Zar, J. H. 1999. Biostatistical Analysis. Prentice-Hall, Inc., Upper Saddle River, New Jersey.
41. Hall, M., F. Eibe, B. Holmes, et al. 2009. The WEKA data mining software: an update. SIGKDD Explor. 11: 10-18.
42. Breiman, L., J. Friedman, R. Olshen, and C. Stone. 1984. Classification and Regression Trees. Wadsworth Publishing Co., Pacific Grove, CA.
43. Dimitrov, J. D., L. T. Roumenina, V. R. Doltchinkova, et al. 2007. Antibodies use heme as a cofactor to extend their pathogen elimination activity and to acquire new effector functions. J. Biol. Chem. 282: 26696-26706.
44. Gonzalez-Dominguez, R., T. Garcia-Barrera, and J. L. Gomez-Ariza. 2014. Combination of metabolomic and phospholipidprofiling approaches for the study of Alzheimer's disease. J. Proteomics 104: 37-47.
45. Ravichandran, K. S. 2010. Find-me and eat-me signals in apoptotic cell clearance: progress and conundrums. J. Exp. Med. 207: 1807-1817.
46. Mapstone, M., A. K. Cheema, M. S. Fiandaca, et al. 2014. Plasma phospholipids identify antecedent memory impairment in older adults. Nat. Med. 20: 415-418.
47. González-Domniguez, R., T. Garcia-Barrera, and J. L. Gómez-Ariza. 2014. Metabolomic study of lipids in serum for biomarker discovery in Alzheimer's disease using direct infusion mass spectrometry. J. Pharm. Biomed. Anal. 98: 321-326.
48. Gonzalez-Dominguez, R., T. Garcia-Barrera, and J. L. Gomez-Ariza. 2014. Using direct infusion mass spectrometry for serum metabolomics in Alzheimer's disease. Anal. Bioanal. Chem. 406: 7137-7148.
49. Nagele, E., M. Han, C. Demarshall, et al. 2011. Diagnosis of Alzheimer's disease based on disease-specific autoantibody profiles in human sera. PLoS One 6: e23112.
50. Maftei, M., F. Thurm, C. Schnack, et al. 2013. Increased levels of antigen-bound beta-amyloid autoantibodies in serum and cerebrospinal fluid of Alzheimer's disease patients. PLoS One 8: e68996.